Tuberous sclerosis complex 1 mRNA (TSC1 mRNA) (TSC1 mRNA)

TSC1 mRNA encodes the protein hamartin, which is a critical component of the TSC1-TSC2 intracellular complex [1]. This complex acts as a negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1) by functioning as a GTPase-activating protein for Rheb [4]. Mutations in the TSC1 gene lead to the loss of functional hamartin, resulting in constitutive activation of mTORC1, which drives uncontrolled cell growth and proliferation [3]. This dysregulation is the primary cause of Tuberous Sclerosis Complex (TSC), a multi-system genetic disorder characterized by benign tumors in various organs, and Lymphangioleiomyomatosis (LAM) [2, 3]. While current pharmacological interventions primarily focus on downstream mTOR inhibitors like everolimus and sirolimus, TSC1 mRNA itself is an emerging target for genetic and transcript-based therapies aimed at restoring tumor suppressor function [3]. Therapeutic approaches under investigation include mRNA replacement strategies to deliver functional transcripts to affected cells. Understanding the stability and translation of TSC1 mRNA is vital for developing these next-generation treatments. The target's role in the mTOR pathway also makes it relevant in various oncology contexts where TSC1 mutations are prevalent [4].

Other names

Hamartin mRNATSC1 transcriptTuberous sclerosis 1 mRNA

Restoration of hamartin protein levels to inhibit the mTORC1 signaling pathway via Rheb GTPase activation; downstream inhibition of mTORC1 by rapalogs.